Abstract

The present disclosure provides in vitro methods for predicting a compound's ability to inhibit multinucleate cell production resulting from post-mitotic cell fusion during a process of Daughter Number Variation (DNV) in mitosis. Compounds identified by this method can be used in cancer treatment, either alone or in combination with other known cancer drugs. The present invention also provides methods of personalized cancer treatment for a patient having a malignant tumor.

IPC Classes  ?

• C12N 5/09 - Tumour cells
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

A method for identifying one or more genomic variations in human genomic DNA, comprising employment of Alu, MIR and SVA sequence-based PCR primers and performing an inter-transposable-element (ITE) polymerase chain reaction on the assay mixture to produce an array of amplicons comprising the ITE genomic segments. Also provided the use of the method for identifying one or more genomic variants associated with a trait or a disease.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

Compositions comprising extracts prepared from mixtures of the herbal plants Radix Bupleurum chinense DC ("B"), Rhizoma Corydalis yanhusuo WT Wang ("Y"), Caulis Polygonum multiflorum Thunb ("P") and Flos Albizia julibrissin Durazz ("A") are provided. The BYP, BYA, BPA, BY, BP, YP and BYPA extracts significantly decreased one or more of the effects of accelerated aging in mice exposed to D-galactose, including spatial memory deficit, and elevated oxidative stress marker malondialdehyde and pro-inflammatory cytokines TNF-alpha and IL-6 in the brain, indicating efficacy in reducing the damage of aging, and preventing and treating Alzheimer's disease and/or Parkinson's disease. Anxiolysis by the BYA, BPA, YPA, BA and PA extracts indicates efficacy for treating anxiety disorders, and the sedative effect of the BYA, YPA and PA extracts indicates efficacy for treating sleep disorders. None of the extracts significantly induced alteration in locomotor activity, decreased muscle coordination, or anterograde amnesia at the maximum oral dose tested.

IPC Classes  ?

• A61K 36/50 - Fumariaceae (Fumitory family), e.g. bleeding heart
• A61K 36/233 - Bupleurum
• A61P 25/22 - Anxiolytics
• A61P 25/20 - HypnoticsSedatives
• A61P 25/16 - Anti-Parkinson drugs

Abstract

In the present application, prediction on the predisposition of a human test subject to cancer is made based on machine learning-assisted comparison of the copy number variations ("CNV") found in the constitutional DNA of the test subject with a set of diagnostic recurrent CNV features (viz. markers) selected from a collection of constitutional DNA samples from noncancer subjects (designated as "Noncancer DNA" samples) plus constitutional DNA samples from cancer patients (designated as "Cancer DNA" samples), all from the same ethnic group as the test subject. Selection and testing of the set of diagnostic recurrent CNV features is performed using a machine learning procedure, exemplified by the CFS-based method, the Frequency-based method and the Classifier-based method, together with the Naive Bayes classification method. Prediction of the test subject's predisposition to cancer is also performed with the Naive Bayes classification method. The cancer patients from whom the constitutional "Cancer DNA" samples are prepared, for the purpose of selection of the diagnostic recurrent CNV features, can consist of patients inflicted with one type of cancer or more than one types of cancers.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids